{"id":"W4366824059","doi":"10.1038/s41591-023-02326-3","title":"Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":318,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Douglas Mental Health University Institute","funders":"University College London; Ionis Pharmaceuticals; Biogen","keywords":"Pathophysiology; Placebo; Alzheimer's disease; Disease; Tau protein; Oligonucleotide; Medicine; Pharmacology; Neuroscience; Internal medicine; Biology; Pathology; Genetics; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00177288,0.001600604,0.003024798,0.000423713,0.000491474,0.0008938782,0.0007932297,0.001922949,0.005265396],"category_scores_gemma":[0.001333406,0.0005284665,0.001347005,0.0003812169,0.0008538723,0.0008145843,0.0002732724,0.002092864,0.0006926113],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004641798,"about_ca_system_score_gemma":0.001070494,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005563213,"about_ca_topic_score_gemma":0.001134134,"domain_scores_codex":[0.9994814,0.0002495613,0.00004368988,0.00009765218,0.00005796879,0.00006964128],"domain_scores_gemma":[0.9993995,0.000168687,0.0001517839,0.00003821184,0.00006230923,0.0001794573],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9629653,0.006351619,0.0003830909,0.001214975,0.0007355299,0.00005970366,0.00004888831,0.0002303899,0.007576041,0.0001365755,0.001039629,0.01925822],"study_design_scores_gemma":[0.9392899,0.05837343,0.0008581681,0.00003824229,0.0002443818,0.00002523506,0.000009099198,0.0002029086,0.0003931072,0.00008001787,0.0004772049,0.000008316626],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9721511,0.01332762,0.001265749,0.001184702,0.0008814004,0.007565013,0.00125846,0.0002334672,0.002132454],"genre_scores_gemma":[0.9716834,0.00777189,0.003118173,0.001777843,0.001002046,0.009734965,0.00110582,0.00002961935,0.00377613],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005265396,"threshold_uncertainty_score":0.01761448,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02776427307319292,"score_gpt":0.3711127497206226,"score_spread":0.3433484766474297,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}